Fig. 6. Association between the Blue_response signature score and the rate of pathological complete response (pCR) in non-TMO-based HER2-positive breast cancer cohorts treated with a combination of chemotherapy and anti-HER2 targeted therapy.   Since direct comparison of signature scores across these non-TMO-based gene expression profiles is currently not feasible, samples within each cohort were stratified using tertile splits of the signature score (i.e. high: > 2/3 percentile; low ≤ 1/3 percentile; medium: ≤ 2/3 percentile and >1/3 percentile).